Bronchogen for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Bronchogen for Health & Longevity

Created on 09/28/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Bronchogen, a lab-made peptide (a short chain of four amino acids) sold as a supplement and research peptide, is promoted for airway resilience with age. Evidence is thin: mostly cell and rat studies, nearly all from its developer, plus one unpublished human report. No harms are documented, reflecting a lack of study rather than demonstrated safety; concerns are product purity, a theoretical growth-promoting signal and delayed evaluation of breathing symptoms. (Full Review)

Protocol

Developer oral course
2 capsules twice daily with food
0.275 g capsules for 30 days, repeated after 3–6 months
Injectable research-peptide approach
500–1,000 µg daily, subcutaneous injection
For 40 days, or 6 days on and 1 off for 7 weeks; no human dose-finding study exists
Conventional lung-health approach
Smoking cessation, vaccination, aerobic training
Pursued with or without peptide courses; in COPD or asthma, courses are layered onto prescribed inhalers, not substituted for them
Time to effect
Bronchitis symptoms
Within a 20–30 day course
Symptom changes described in the developer clinical report
Lung-function change
Repeat spirometry over months
Required to confirm any lung-function change
Airway lining repair
After one month
Timepoint assessed in rat studies; animal data only

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • Anyone under 18 years of age
  • Active cancer, or a lung nodule under evaluation (Lung-RADS category 3–4 on low-dose CT)
  • Acute breathing problems (resting oxygen saturation below 92% or breathlessness at rest)
  • Known hypersensitivity to the peptide or capsule ingredients, including lactose
  • Severe immunosuppression (absolute neutrophil count below 1,000 cells/µL) for injectable products
    •
Key Interactions
  • Prescription inhaled therapies (tiotropium, salmeterol, budesonide): Monitor; prescribed inhalers continue unchanged
  • Prescription cancer therapies (osimertinib, pembrolizumab, platinum chemotherapy, meaning platinum-based cell-killing drugs): Caution; use deferred during active cancer treatment unless reviewed by the treating oncologist
  • Prescription immunosuppressants (immune-dampening drugs: prednisone, methotrexate, tacrolimus): Caution with injectable products
  • Over-the-counter cough and mucus medicines (guaifenesin, dextromethorphan): Monitor; cough beyond 8 weeks prompts medical assessment
  • Other Khavinson peptide supplements (Chonluten, Taxorest, Thymalin): Monitor; one new peptide at a time, at least 2 weeks apart
  • Supplements with additive airway effects (N-acetylcysteine 600–1,200 mg/day): Monitor; separate start dates
  • Smoking and vaping: Caution, counteracting effect
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low:
  • Speculative: Theoretical promotion of abnormal cell growth; contaminated, mislabeled or non-sterile products; delayed care for progressive lung disease; digestive upset and allergic reactions
    •

Monitoring

Marker Target Why
FEV1/FVC ratio ≥ 0.75 Detects airflow obstruction
FEV1 (% predicted) ≥ 90% of predicted Tracks lung-function change
SpO2 at rest 96–99% Screens gas exchange
hs-CRP < 1.0 mg/L General inflammation marker
Blood eosinophils 100–300 cells/µL Flags allergic-type airway inflammation
ALT < 25 U/L Liver safety baseline
eGFR > 90 mL/min/1.73 m² Kidney function baseline

Cadence: Baseline before a first course; symptoms at 2 and 4 weeks; spirometry and SpO2 after each 30-day course, then every 6–12 months while courses continue; blood tests yearly or after injectable courses

Qualitative Assessment

  • Daily cough and sputum frequency
  • Breathlessness on stairs or exertion (0–4 breathlessness scale)
  • Chest infections or flare-ups per year
  • Exercise tolerance, such as a timed walk
  • Sleep disruption from nighttime cough
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.